Product
PCV24
PCV24
World’s first 24-valent pneumococcal polysaccharide conjugate vaccine with dual carrier proteins
-
Innovative Design
QbD with implementation of modern technology for better vaccines.
-
Outstanding immunogenicity and memory with minimal carrier-induced inhibition
Eliciting higher levels of specific antibodies compared to licensed PCV products.
-
Manufacturing capability
Independently developed the capability from scratch to the manufacturing scale with in-depth understanding of the product and the process by implementing advanced technology and QbD, simplifying complex processes for this highly challenging product.
-
Protection for infants, adults and the elderly
The vaccine is applicable to the people aged 2 months and older. It offers better prevention against pneumococcal infectious disease and herd immunity.
-
Broad spectrum of protection
Protect against 24 major pathogenic pneumococcal serotypes, the broadest coverage so far.
Innovative Design
Outstanding immunogenicity and memory with minimal carrier-induced inhibition
Manufacturing capability
Protection for infants, adults and the elderly
Broad spectrum of protection
Pipeline
Pipeline
Current Situation
Expected Situation
Disease Areas
Projects
Types
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
-
Bacterial infectionPCV24 for AdultsNovel Vaccine
-
Bacterial infectionPCV24 for InfantsNovel Vaccine
-
Bacterial infectionMultivalent Meningococcal Conjugate VaccineNovel Vaccine
-
Viral infectionMultivalent Norovirus VaccineNovel Vaccine
-
Viral infectionMultivalent Rotavirus VaccineNovel Vaccine
-
Bacterial infectionMultivalent Polysaccharide Conjugate VaccineNovel Vaccine
-
Bacterial infectionCombined Multivalent VaccineNovel Vaccine
-
Bacterial infectionTherapeutic AntibodyNovel Antibody
-
Bacterial infectionInnovative Multivalent VaccineNovel Vaccine
-
Bacterial infectionTherapeutic AntibodyNovel Antibody
1
Disease Areas
Bacterial infection
Projects
PCV24 for Adults
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
2
Disease Areas
Bacterial infection
Projects
PCV24 for Infants
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
3
Disease Areas
Bacterial infection
Projects
Multivalent Meningococcal Conjugate Vaccine
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
4
Disease Areas
Viral infection
Projects
Multivalent Norovirus Vaccine
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
5
Disease Areas
Viral infection
Projects
Multivalent Rotavirus Vaccine
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
6
Disease Areas
Bacterial infection
Projects
Multivalent Polysaccharide Conjugate Vaccine
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
7
Disease Areas
Bacterial infection
Projects
Combined Multivalent Vaccine
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
8
Disease Areas
Bacterial infection
Projects
Therapeutic Antibody
Types
Novel Antibody
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
9
Disease Areas
Bacterial infection
Projects
Innovative Multivalent Vaccine
Types
Novel Vaccine
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
10
Disease Areas
Bacterial infection
Projects
Therapeutic Antibody
Types
Novel Antibody
Discovery
Pre-clinical
Pilot Process
IND
Phase I
Phase II
Phase III
Reinovax WeChat official account
Friendship link: Changchun High-tech Group